Likewise, in CGGA, high LYN expression predicted worse survival in glioma patients regarding different IDH statuses (p = 0.0331, p < 0.001, respectively; Figure 3), radiotherapy statuses (p = 0.0961, p < 0.001, respectively; Figure 3), chemotherapy statuses (p = 0.1377, p = 0.0735, respectively; Figure 3), 1p19q statuses (p < 0.001, p = 0.2452, respectively; Figure 3), and with MGMT promotor statuses (p < 0.001, respectively; Figure 3). The gene discussed is IDH1; the disease is central nervous system cancer.